Cargando…

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy. It refined...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, Kathy S., André, Fabrice, Bergh, Jonas, Bonnefoi, Hervé, Bretel-Morales, Denisse, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Coates, Alan S., Colleoni, Marco, Costa, Alberto, Curigliano, Giuseppe, Davidson, Nancy E., Di Leo, Angelo, Ejlertsen, Bent, Forbes, John F., Gelber, Richard D., Gnant, Michael, Goldhirsch, Aron, Goodwin, Pamela, Goss, Paul E., Harris, Jay R., Hayes, Daniel F., Hudis, Clifford A., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Loibl, Sibylle, Morrow, Monica, Namer, Moise, Kent Osborne, C., Partridge, Ann H., Penault-Llorca, Frédérique, Perou, Charles M., Piccart-Gebhart, Martine J., Pritchard, Kathleen I., Rutgers, Emiel J.T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, Tutt, Andrew, Untch, Michael, Viale, Giuseppe, Watanabe, Toru, Wilcken, Nicholas, Winer, Eric P., Wood, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755334/
https://www.ncbi.nlm.nih.gov/pubmed/23917950
http://dx.doi.org/10.1093/annonc/mdt303
_version_ 1782281980094709760
author Goldhirsch, A.
Winer, E. P.
Coates, A. S.
Gelber, R. D.
Piccart-Gebhart, M.
Thürlimann, B.
Senn, H.-J.
Albain, Kathy S.
André, Fabrice
Bergh, Jonas
Bonnefoi, Hervé
Bretel-Morales, Denisse
Burstein, Harold
Cardoso, Fatima
Castiglione-Gertsch, Monica
Coates, Alan S.
Colleoni, Marco
Costa, Alberto
Curigliano, Giuseppe
Davidson, Nancy E.
Di Leo, Angelo
Ejlertsen, Bent
Forbes, John F.
Gelber, Richard D.
Gnant, Michael
Goldhirsch, Aron
Goodwin, Pamela
Goss, Paul E.
Harris, Jay R.
Hayes, Daniel F.
Hudis, Clifford A.
Ingle, James N.
Jassem, Jacek
Jiang, Zefei
Karlsson, Per
Loibl, Sibylle
Morrow, Monica
Namer, Moise
Kent Osborne, C.
Partridge, Ann H.
Penault-Llorca, Frédérique
Perou, Charles M.
Piccart-Gebhart, Martine J.
Pritchard, Kathleen I.
Rutgers, Emiel J.T.
Sedlmayer, Felix
Semiglazov, Vladimir
Shao, Zhi-Ming
Smith, Ian
Thürlimann, Beat
Toi, Masakazu
Tutt, Andrew
Untch, Michael
Viale, Giuseppe
Watanabe, Toru
Wilcken, Nicholas
Winer, Eric P.
Wood, William C.
author_facet Goldhirsch, A.
Winer, E. P.
Coates, A. S.
Gelber, R. D.
Piccart-Gebhart, M.
Thürlimann, B.
Senn, H.-J.
Albain, Kathy S.
André, Fabrice
Bergh, Jonas
Bonnefoi, Hervé
Bretel-Morales, Denisse
Burstein, Harold
Cardoso, Fatima
Castiglione-Gertsch, Monica
Coates, Alan S.
Colleoni, Marco
Costa, Alberto
Curigliano, Giuseppe
Davidson, Nancy E.
Di Leo, Angelo
Ejlertsen, Bent
Forbes, John F.
Gelber, Richard D.
Gnant, Michael
Goldhirsch, Aron
Goodwin, Pamela
Goss, Paul E.
Harris, Jay R.
Hayes, Daniel F.
Hudis, Clifford A.
Ingle, James N.
Jassem, Jacek
Jiang, Zefei
Karlsson, Per
Loibl, Sibylle
Morrow, Monica
Namer, Moise
Kent Osborne, C.
Partridge, Ann H.
Penault-Llorca, Frédérique
Perou, Charles M.
Piccart-Gebhart, Martine J.
Pritchard, Kathleen I.
Rutgers, Emiel J.T.
Sedlmayer, Felix
Semiglazov, Vladimir
Shao, Zhi-Ming
Smith, Ian
Thürlimann, Beat
Toi, Masakazu
Tutt, Andrew
Untch, Michael
Viale, Giuseppe
Watanabe, Toru
Wilcken, Nicholas
Winer, Eric P.
Wood, William C.
author_sort Goldhirsch, A.
collection PubMed
description The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy. It refined its earlier approach to the classification and management of luminal disease in the absence of amplification or overexpression of the Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged recommendations for the systemic adjuvant therapy of HER2-positive and ‘triple-negative’ disease. The Panel again accepted that conventional clinico-pathological factors provided a surrogate subtype classification, while noting that in those areas of the world where multi-gene molecular assays are readily available many clinicians prefer to base chemotherapy decisions for patients with luminal disease on these genomic results rather than the surrogate subtype definitions. Several multi-gene molecular assays were recognized as providing accurate and reproducible prognostic information, and in some cases prediction of response to chemotherapy. Cost and availability preclude their application in many environments at the present time. Broad treatment recommendations are presented. Such recommendations do not imply that each Panel member agrees: indeed, among more than 100 questions, only one (trastuzumab duration) commanded 100% agreement. The various recommendations in fact carried differing degrees of support, as reflected in the nuanced wording of the text below and in the votes recorded in supplementary Appendix S1, available at Annals of Oncology online. Detailed decisions on treatment will as always involve clinical consideration of disease extent, host factors, patient preferences and social and economic constraints.
format Online
Article
Text
id pubmed-3755334
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-37553342013-08-28 Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Goldhirsch, A. Winer, E. P. Coates, A. S. Gelber, R. D. Piccart-Gebhart, M. Thürlimann, B. Senn, H.-J. Albain, Kathy S. André, Fabrice Bergh, Jonas Bonnefoi, Hervé Bretel-Morales, Denisse Burstein, Harold Cardoso, Fatima Castiglione-Gertsch, Monica Coates, Alan S. Colleoni, Marco Costa, Alberto Curigliano, Giuseppe Davidson, Nancy E. Di Leo, Angelo Ejlertsen, Bent Forbes, John F. Gelber, Richard D. Gnant, Michael Goldhirsch, Aron Goodwin, Pamela Goss, Paul E. Harris, Jay R. Hayes, Daniel F. Hudis, Clifford A. Ingle, James N. Jassem, Jacek Jiang, Zefei Karlsson, Per Loibl, Sibylle Morrow, Monica Namer, Moise Kent Osborne, C. Partridge, Ann H. Penault-Llorca, Frédérique Perou, Charles M. Piccart-Gebhart, Martine J. Pritchard, Kathleen I. Rutgers, Emiel J.T. Sedlmayer, Felix Semiglazov, Vladimir Shao, Zhi-Ming Smith, Ian Thürlimann, Beat Toi, Masakazu Tutt, Andrew Untch, Michael Viale, Giuseppe Watanabe, Toru Wilcken, Nicholas Winer, Eric P. Wood, William C. Ann Oncol Special Article The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy. It refined its earlier approach to the classification and management of luminal disease in the absence of amplification or overexpression of the Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged recommendations for the systemic adjuvant therapy of HER2-positive and ‘triple-negative’ disease. The Panel again accepted that conventional clinico-pathological factors provided a surrogate subtype classification, while noting that in those areas of the world where multi-gene molecular assays are readily available many clinicians prefer to base chemotherapy decisions for patients with luminal disease on these genomic results rather than the surrogate subtype definitions. Several multi-gene molecular assays were recognized as providing accurate and reproducible prognostic information, and in some cases prediction of response to chemotherapy. Cost and availability preclude their application in many environments at the present time. Broad treatment recommendations are presented. Such recommendations do not imply that each Panel member agrees: indeed, among more than 100 questions, only one (trastuzumab duration) commanded 100% agreement. The various recommendations in fact carried differing degrees of support, as reflected in the nuanced wording of the text below and in the votes recorded in supplementary Appendix S1, available at Annals of Oncology online. Detailed decisions on treatment will as always involve clinical consideration of disease extent, host factors, patient preferences and social and economic constraints. Oxford University Press 2013-09 2013-08-04 /pmc/articles/PMC3755334/ /pubmed/23917950 http://dx.doi.org/10.1093/annonc/mdt303 Text en © The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Special Article
Goldhirsch, A.
Winer, E. P.
Coates, A. S.
Gelber, R. D.
Piccart-Gebhart, M.
Thürlimann, B.
Senn, H.-J.
Albain, Kathy S.
André, Fabrice
Bergh, Jonas
Bonnefoi, Hervé
Bretel-Morales, Denisse
Burstein, Harold
Cardoso, Fatima
Castiglione-Gertsch, Monica
Coates, Alan S.
Colleoni, Marco
Costa, Alberto
Curigliano, Giuseppe
Davidson, Nancy E.
Di Leo, Angelo
Ejlertsen, Bent
Forbes, John F.
Gelber, Richard D.
Gnant, Michael
Goldhirsch, Aron
Goodwin, Pamela
Goss, Paul E.
Harris, Jay R.
Hayes, Daniel F.
Hudis, Clifford A.
Ingle, James N.
Jassem, Jacek
Jiang, Zefei
Karlsson, Per
Loibl, Sibylle
Morrow, Monica
Namer, Moise
Kent Osborne, C.
Partridge, Ann H.
Penault-Llorca, Frédérique
Perou, Charles M.
Piccart-Gebhart, Martine J.
Pritchard, Kathleen I.
Rutgers, Emiel J.T.
Sedlmayer, Felix
Semiglazov, Vladimir
Shao, Zhi-Ming
Smith, Ian
Thürlimann, Beat
Toi, Masakazu
Tutt, Andrew
Untch, Michael
Viale, Giuseppe
Watanabe, Toru
Wilcken, Nicholas
Winer, Eric P.
Wood, William C.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
title Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
title_full Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
title_fullStr Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
title_full_unstemmed Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
title_short Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
title_sort personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2013
topic Special Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755334/
https://www.ncbi.nlm.nih.gov/pubmed/23917950
http://dx.doi.org/10.1093/annonc/mdt303
work_keys_str_mv AT goldhirscha personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT winerep personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT coatesas personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT gelberrd personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT piccartgebhartm personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT thurlimannb personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT sennhj personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT albainkathys personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT andrefabrice personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT berghjonas personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT bonnefoiherve personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT bretelmoralesdenisse personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT bursteinharold personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT cardosofatima personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT castiglionegertschmonica personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT coatesalans personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT colleonimarco personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT costaalberto personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT curiglianogiuseppe personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT davidsonnancye personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT dileoangelo personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT ejlertsenbent personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT forbesjohnf personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT gelberrichardd personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT gnantmichael personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT goldhirscharon personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT goodwinpamela personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT gosspaule personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT harrisjayr personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT hayesdanielf personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT hudisclifforda personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT inglejamesn personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT jassemjacek personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT jiangzefei personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT karlssonper personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT loiblsibylle personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT morrowmonica personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT namermoise personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT kentosbornec personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT partridgeannh personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT penaultllorcafrederique personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT peroucharlesm personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT piccartgebhartmartinej personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT pritchardkathleeni personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT rutgersemieljt personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT sedlmayerfelix personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT semiglazovvladimir personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT shaozhiming personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT smithian personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT thurlimannbeat personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT toimasakazu personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT tuttandrew personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT untchmichael personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT vialegiuseppe personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT watanabetoru personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT wilckennicholas personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT winerericp personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013
AT woodwilliamc personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013